CN1659171A - 新用途或环木脂体以及新环木脂体 - Google Patents

新用途或环木脂体以及新环木脂体 Download PDF

Info

Publication number
CN1659171A
CN1659171A CN028162404A CN02816240A CN1659171A CN 1659171 A CN1659171 A CN 1659171A CN 028162404 A CN028162404 A CN 028162404A CN 02816240 A CN02816240 A CN 02816240A CN 1659171 A CN1659171 A CN 1659171A
Authority
CN
China
Prior art keywords
compound
och
igf
formula
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN028162404A
Other languages
English (en)
Chinese (zh)
Inventor
奥利·拉森
马格努斯·阿克塞尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axelar AB
Original Assignee
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum AB filed Critical Biovitrum AB
Publication of CN1659171A publication Critical patent/CN1659171A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/70—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with ring systems containing two or more relevant rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN028162404A 2001-06-19 2002-06-19 新用途或环木脂体以及新环木脂体 Pending CN1659171A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE01021682 2001-06-19
SE0102168A SE0102168D0 (sv) 2001-06-19 2001-06-19 New use and new compounds
US30043101P 2001-06-26 2001-06-26
US60/300,431 2001-06-26

Publications (1)

Publication Number Publication Date
CN1659171A true CN1659171A (zh) 2005-08-24

Family

ID=20284528

Family Applications (3)

Application Number Title Priority Date Filing Date
CN028162404A Pending CN1659171A (zh) 2001-06-19 2002-06-19 新用途或环木脂体以及新环木脂体
CNA2009101347598A Pending CN101606929A (zh) 2001-06-19 2002-06-19 苦鬼臼脂素的用途
CNB028161904A Expired - Fee Related CN100503611C (zh) 2001-06-19 2002-06-19 特定环木脂体的新用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CNA2009101347598A Pending CN101606929A (zh) 2001-06-19 2002-06-19 苦鬼臼脂素的用途
CNB028161904A Expired - Fee Related CN100503611C (zh) 2001-06-19 2002-06-19 特定环木脂体的新用途

Country Status (15)

Country Link
US (7) US7348358B2 (https=)
EP (5) EP1397369A1 (https=)
JP (2) JP2004534078A (https=)
KR (1) KR100940055B1 (https=)
CN (3) CN1659171A (https=)
AT (1) ATE441411T1 (https=)
AU (2) AU2002311731B8 (https=)
CA (2) CA2451047C (https=)
DK (1) DK1498121T3 (https=)
ES (1) ES2333014T3 (https=)
NO (1) NO332642B1 (https=)
NZ (2) NZ530172A (https=)
PT (1) PT1498121E (https=)
SE (1) SE0102168D0 (https=)
WO (2) WO2002102805A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104434909A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种去氧鬼臼毒素作为胰岛素样生长因子受体拮抗剂用途

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102168D0 (sv) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
SE0203747D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New use
SE0203746D0 (sv) * 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
SE0301202D0 (sv) * 2003-04-24 2003-04-24 Orteca Ab C O Karolinska Innov New use and new compounds
US7342114B2 (en) 2003-07-01 2008-03-11 California Pacific Medical Center Podophyllotoxin derivatives
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
KR100872204B1 (ko) * 2003-10-15 2008-12-09 오에스아이 파마슈티컬스, 인코포레이티드 이미다조피라진 티로신 키나제 억제제
ATE514434T1 (de) 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc Hemmer des insulinartigen wachstumsfaktor- rezeptors-1 zur hemmung von tumorzellwachstum
ATE384700T1 (de) 2004-03-12 2008-02-15 Analytecon Sa Tetrahydroisochinolin- und tetrahydrobenzazepin derivative als igf-1r inhibitoren
TWI378934B (en) * 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
AU2006292278B2 (en) 2005-09-20 2012-03-08 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
AU2007218217A1 (en) * 2006-02-24 2007-08-30 Axelar Ab Use of cyclolignans for the treatment of type 2 diabetes and as contraceptives
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California Small molecule potentiator of hormonal therapy for breast cancer
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
WO2009100349A1 (en) * 2008-02-09 2009-08-13 The Trustees Of Columbia University In The City Of New York Analogues of (-)-picropodophyllin, synthesis and uses thereof
WO2009108857A2 (en) * 2008-02-27 2009-09-03 Combithera, Inc. Combination therapy for prostate cancer
EP2274617A4 (en) * 2008-04-10 2011-11-09 Massachusetts Inst Technology METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
WO2010054264A1 (en) 2008-11-07 2010-05-14 Triact Therapeutics, Inc. Use of catecholic butane derivatives in cancer therapy
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
JP2012519282A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
WO2010138686A1 (en) * 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
US7924203B2 (en) * 2009-06-12 2011-04-12 Analog Devices, Inc. Most significant bits analog to digital converter, and an analog to digital converter including a most significant bits analog to digital converter
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
CA2783656A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103189381B (zh) 2010-08-31 2016-06-08 阿克塞拉公司 制备环木脂体的新方法
EP2624827A4 (en) 2010-10-08 2014-05-28 Axelar Ab PICROPODOPHYLLINE B OR C POLYMORPHIC FOR USE IN ANTICANCER THERAPY
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
JP5892508B2 (ja) * 2011-05-23 2016-03-23 国立大学法人 鹿児島大学 抗腫瘍剤及びその製造方法
WO2013124382A1 (en) * 2012-02-24 2013-08-29 Nestec S.A. Peltatin for use in the treatment of cardiovascular disorders
WO2013132262A1 (en) 2012-03-09 2013-09-12 Axelar Ab Picropodophyllin derivatives
WO2013132263A1 (en) 2012-03-09 2013-09-12 Axelar Ab Picropodophyllin derivatives for use in therapy
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
JP5923375B2 (ja) * 2012-04-24 2016-05-24 花王株式会社 Ｃｇｒｐ応答性促進剤
WO2014102889A1 (ja) * 2012-12-25 2014-07-03 国立大学法人鹿児島大学 抗腫瘍剤及びその製造方法
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
CA2912254C (en) 2013-05-10 2021-06-08 M. Alphabet 2, L.L.C. Methods of treating skin conditions using cyclolignan compounds
US9381246B2 (en) 2013-09-09 2016-07-05 Triact Therapeutics, Inc. Cancer therapy
WO2015168255A1 (en) 2014-04-29 2015-11-05 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
JP6550538B2 (ja) 2015-10-27 2019-07-24 カリフォルニア パシフィック メディカル センター ポドフィロトキシン誘導体およびそれらの使用
US10087194B2 (en) 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
CN110669054B (zh) * 2018-07-03 2022-04-26 南京药石科技股份有限公司 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途
KR102378151B1 (ko) * 2020-05-11 2022-03-24 주식회사 제이앤씨사이언스 베타-아포피크로포도필린의 신규한 유도체

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2825730A (en) * 1953-02-04 1958-03-04 Thompson Boyce Plant Res Organic compounds
US4342777A (en) * 1979-03-29 1982-08-03 The United States Of America As Represented By The Secretary Of Agriculture Polybutylbenzylphenols and benzyl-3,4-methylenedioxybenzenes in insect population control
HU201672B (en) 1984-12-28 1990-12-28 Conpharm Ab Process for producing pharmaceutical compositions comprising podophyllotoxin
US4771072A (en) * 1985-01-10 1988-09-13 Tanabe Seiyaku Co., Ltd. Alkoxynaphthalene derivatives
SE468213B (sv) * 1986-06-27 1992-11-23 Conpharm Ab Anvaendning av podophyllotoxin eller ett derivat daerav till framstaellning av en farmakologisk beredning foer behandling av kollagenoser, saerskilt reumatoid artrit
WO1988003800A1 (en) * 1986-11-19 1988-06-02 Chemex Pharmaceuticals, Inc. Lipoxygenase inhibitors
SE464167B (sv) * 1989-07-31 1991-03-18 Analytecon Sa Topisk farmaceutisk beredning av podophyllotoxin
CN1075316A (zh) 1992-10-22 1993-08-18 布里斯托尔-米尔斯·斯奎布公司 表鬼臼毒中间体的制备方法
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
JPH09194368A (ja) * 1996-01-11 1997-07-29 Pola Chem Ind Inc ポドフィロトキシン誘導体及びそれからなる新規細胞分化誘導剤
US5726027A (en) 1996-03-08 1998-03-10 The Regents Of The University Of California Method for treatment of insulin resistance
DE69834828T2 (de) * 1997-11-27 2007-01-04 Commonwealth Scientific And Industrial Research Organisation Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462)
JP2002519335A (ja) 1998-06-26 2002-07-02 クアナム メディカル コーポレイション 再狭窄の予防のためのトポイソメラーゼインヒビター
CA2397871A1 (en) 2000-01-20 2001-07-26 Supratek Pharma Inc. Novel podophyllotoxin compositions
EP1335922B1 (en) * 2000-11-20 2006-09-13 Song-Bae Kim Process for preparing 4'-demethyl-4'-O-substituted-1-deoxypodophyllotoxin derivatives and geometric isomers thereof and anti-cancer composition comprising the same
SE0102168D0 (sv) * 2001-06-19 2001-06-19 Karolinska Innovations Ab New use and new compounds
WO2004094409A1 (en) * 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
SE0301202D0 (sv) * 2003-04-24 2003-04-24 Orteca Ab C O Karolinska Innov New use and new compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104434909A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种去氧鬼臼毒素作为胰岛素样生长因子受体拮抗剂用途

Also Published As

Publication number Publication date
AU2002311731B8 (en) 2009-10-29
JP2005500300A (ja) 2005-01-06
AU2002311731B2 (en) 2009-02-26
CA2455328C (en) 2011-09-20
US7629381B2 (en) 2009-12-08
NO20035648D0 (no) 2003-12-17
WO2002102804A8 (en) 2004-05-13
US20080221207A1 (en) 2008-09-11
CN100503611C (zh) 2009-06-24
DK1498121T3 (da) 2009-12-14
EP1938819A3 (en) 2010-04-07
CN1543466A (zh) 2004-11-03
JP5071910B2 (ja) 2012-11-14
EP1498121B1 (en) 2009-09-02
US7709526B2 (en) 2010-05-04
EP1938819A2 (en) 2008-07-02
AU2002311731C1 (en) 2009-09-03
EP1938818A2 (en) 2008-07-02
US8389747B2 (en) 2013-03-05
KR20040007743A (ko) 2004-01-24
US20040186169A1 (en) 2004-09-23
EP1498121A1 (en) 2005-01-19
ES2333014T3 (es) 2010-02-16
NZ530290A (en) 2005-05-27
CA2451047A1 (en) 2002-12-27
CA2455328A1 (en) 2002-12-27
EP1938818A3 (en) 2010-04-07
NO332642B1 (no) 2012-11-26
EP1397369A1 (en) 2004-03-17
US20100216728A1 (en) 2010-08-26
US20060154982A1 (en) 2006-07-13
WO2002102805A1 (en) 2002-12-27
PT1498121E (pt) 2009-12-04
JP2004534078A (ja) 2004-11-11
EP2186513A1 (en) 2010-05-19
US20080119528A1 (en) 2008-05-22
CA2451047C (en) 2012-10-09
SE0102168D0 (sv) 2001-06-19
US7348358B2 (en) 2008-03-25
WO2002102804A1 (en) 2002-12-27
KR100940055B1 (ko) 2010-02-04
ATE441411T1 (de) 2009-09-15
CN101606929A (zh) 2009-12-23
US20040167208A1 (en) 2004-08-26
US20090326248A1 (en) 2009-12-31
NZ530172A (en) 2004-12-24
NO20035648L (no) 2004-02-18
AU2002314671B2 (en) 2008-09-18
US7662851B2 (en) 2010-02-16

Similar Documents

Publication Publication Date Title
CN1659171A (zh) 新用途或环木脂体以及新环木脂体
AU2002314671A1 (en) New use of cyclolignans and new cyclolignans
AU2002311731A1 (en) New use of specific cyclolignans
Mereyala et al. Cytotoxic activity of styryl lactones and their derivatives
US20070123491A1 (en) Podophyllotoxin derivatives as igf-1r inhibitors
WO2004055022A1 (en) Use of cyclolignans as inhibitors of igf-1 receptor for treatment of malignat diseases
AU2009201542B2 (en) New use of specific cyclolignans
CA2182878C (en) Novel cytotoxic macrolides and methods of use
EP1397368A1 (en) New use of specific cyclolignans

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: AXELAR AB

Free format text: FORMER OWNER: BIOVITRUM AB

Effective date: 20060317

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060317

Address after: Stockholm

Applicant after: Axelar AB

Address before: Stockholm

Applicant before: Biovitrum AB

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication